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SObjective:Radical thymectomy has becomemore popular in the comprehensive treatment ofmyasthenia gravis.
Minimally invasive techniques are increasingly used for thymectomy. The most recent development in robotic
thoracoscopic surgery has been successfully applied for mediastinal pathologies. To establish robotic technique
as a standard, the results of high-volume centers and comparison with traditional surgery are mandatory.
Methods: In a retrospective cohort study, the results of 79 thoracoscopic thymectomies (October 1994 to
December 2002) were compared with the results of 74 robotic thoracoscopic thymectomies (January 2003 to
August 2006). Data from both series were collected prospectively. In both groups, all patients had myasthenia
gravis. Both cohorts were compared with respect to severity of disease, gender, age, histology, and postoperative
morbidity. All patients were analyzed for quantification of improvement of disease according to the Myasthenia
Gravis Foundation of America.
Results: There were no differences in age distribution and severity of myasthenia gravis. The dominant histo-
logic finding was follicular hyperplasia of the thymus in both groups with a significantly higher percentage in the
thoracoscopic thymectomy series (68% vs 45%, P<.001). After a follow-up of 42 months, the cumulative com-
plete remission rate of myasthenia gravis for robotic and nonrobotic thymectomy was 39.25% and 20.3%
(P ¼ .01), respectively.
Conclusions: There is an improved outcome for myasthenia gravis after robotic thoracoscopic thymectomy
compared with thoracoscopic thymectomy. (J Thorac Cardiovasc Surg 2011;141:673-7)Thymectomy has been held by many to be an important part
of the treatment of nonthymomatous myasthenia gravis, al-
though this assertion has never been proven by a prospective
randomized trial.1,2 The development of minimally invasive
surgery has led to an increased acceptance of thymectomy.
This is due to sufficient radicality and decreased morbidity
and mortality after thoracoscopic thymectomy.3-5 The
introduction of the da Vinci robotic system (Intuitive
Surgical, Inc, Sunnyvale, Calif) was a further step in the
development of minimally invasive radical thymectomy.3,6
The ergonomic benefits of this system in mediastinal
surgery have been described.3,7 The da Vinci robotic
system allows for new technical refinements of the well-
defined thoracoscopic technique for thymectomy. Generally,
robotic surgical procedures have a shorter learning curve.8
The aim of this studywas to evaluate the incremental benefits
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The Journal of Thoracic and Cadard thoracoscopic thymectomy in the setting of patients
with myasthenia gravis. Therefore, this study sought to com-
pare the results of a large series of robotic thymectomieswith
the alternative thoracoscopic nonrobotic technique based on
a single-center experience.PATIENTS AND METHODS
Patients
A retrospective cohort study analyzed 74 consecutive robotic and 79 con-
secutive thoracoscopic thymectomies that were performed between October
1994 andAugust 2006.The indication for thymectomy includedpatientswith
myasthenia gravis. All study data were collected prospectively. The clinical
diagnosis of myasthenia gravis was made by a neurologist. The degree of se-
verity of myasthenia gravis was measured according to the classification of
the Myasthenia Gravis Foundation of America (MGFA).9 All patients re-
ceived preoperative thoracic computed tomography scans or in some cases
magnetic resonance imaging. Surgery was performed in a 3-trocar left-
sided thoracoscopic technique with or without the da Vinci robotic system.
This telematic system for robotic-assisted surgery consists of 3 parts: the sur-
geon’s console, the surgical arm cart, and the image processing equipment.
Assignment to onegroup or the otherwas based on the era of surgery. Patients
from the earlier era (October 1994 to December 2002) had a thoracoscopic
operation, and patients in the subsequent era (January 2003 to August
2006) had a robotic operation. The only exception included advanced thy-
moma with necessity of a sternotomy. The robotic technique was modified
on the basis of the elaborated thoracoscopic procedure as described next.
Surgical Technique
The patient is placed in a right 30-degree antidecubitus position. With
single right lung ventilation, the camera trocar is positioned in the fourth in-
tercostal space at the anterior axillary line. The second trocar is placed in
a cranial position in the third intercostal space at the anterior to middlerdiovascular Surgery c Volume 141, Number 3 673
TABLE 1. Clinical characteristics of patients who underwent 79
thoracoscopic and 74 robotic thymectomies between October 1994
and August 2006
Thoracoscopic (%)
n ¼ 79
Robotic (%)
n ¼ 74
Sex ratio (F:M) 2.4:1 1.3:1
Age, y
<19 7 (9) 7 (10)
19–40 39 (49) 35 (47)
>40 33 (42) 32 (43)
MGFA
I 3 (4) 4 (5)
II 26 (33) 25 (34)
III 34 (43) 35 (47)
IV 15 (19) 10 (14)
V 1 (1) 0
MGFA, Myasthenia Gravis Foundation of America.
Abbreviation and Acronym
MGFA ¼ Myasthenia Gravis Foundation of
America
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Saxillary line. The third trocar is located caudally in the fifth intercostal space
at the mid-clavicular line. Thus, all 3 trocars are placed exactly along the
submammary fold. The special trocars are connected with the 3 robotic
arms of the table cart. The point of reference at the beginning of the resection
in the anterior mediastinum is the left phrenic nerve. The thymic gland may
be partially visible depending on the various amounts of pericardial fatty tis-
sue and the thymic histology. Preparation starts caudally in themiddle of the
pericardiumwhere there is always an area with little fat content. The en bloc
resection is continued to the right until the subxiphoid pleural fold is reached.
Then the retrosternal pleural incision is continued up to the jugular fold of
the mediastinal pleura. Beginning at the caudal pericardium, the tissue
bloc is further mobilized on the pericardium. The aorto-caval groove is dis-
sected free. To continue the preparation into the neck from behind themanu-
brium sterni, the mediastinal fold is incised. The majority of cases reveals 2
to 4 thymic veins. These veins have to be dissected without injury to the in-
nominate vein. The upper poles, mobilized after careful dissection of their
capsule, are gently grasped and then pulled down. The en bloc resected spec-
imen of the thymus with all surrounding fatty tissue is placed in an endobag
and then removed through one of the trocar incisions. The right pleural cav-
ity is opened for additional control of radical resection.A chest tube is placed
in the left pleural cavity. After the operation, the patient is immediately ex-
tubated and put on patient-controlled analgesia. The chest drain is removed
if the postoperative chest x-ray shows normal findings and the amount of
secretion is less than 100 mL during the first 12 hours postoperatively.
Two technical modifications were applied to the robotic procedure to al-
low for more space in the mediastinum, the lifting of the chest wall with the
stable camera port and the insufflation with CO2 at a pressure of approxi-
mately 5 mm Hg.
To evaluate possible advantages of robotic thoracoscopic thymectomy,
the design of a cohort study was chosen. Consequently, the first 74 robotic
thoracoscopic thymectomies were compared with the entire series of
79 thoracoscopic thymectomies. The main outcome parameter was com-
plete remission according to the classification of the MGFA.9 As recom-
mended by the MGFA, a complete remission was considered at least
after 1 year of follow-up. The maximum follow-up for the thoracoscopic
and robotic groups was 174 and 84 months, respectively. To allow for
a cohort study, we used a unified follow-up of 42 months for each patient
in both groups. This was the minimum follow-up that was determined by
the last patient in the robotic series. Peri- and postoperative morbidity
and mortality for both procedures were examined. To show comparability
of both groups, factors such as histology, patient’s age, severity of myasthe-
nia gravis, and gender distribution were analyzed.
The Kaplan–Meier method, as recommended by the MGFA, was used
for the analysis of remissions after thymectomy.9 Statistical analysis was
performed using the log-rank test when appropriate.RESULTS
All thymectomies were performed by one team at the De-
partment of Surgery of Charite-Universit€atsmedizin, Cam-
pus Mitte, Berlin, Germany. The demographic data of
these patients are shown in Table 1. The thoracoscopic sur-
gical technique was developed as a 10-step-standardized
procedure. After the clinical introduction of the da Vinci ro-
botic system in December 2002, almost all thymectomies674 The Journal of Thoracic and Cardiovascular Surgwere then performed using this system. The technical ad-
vantages of the da Vinci robotic system were adapted to
the 10 steps of the thoracoscopic technique. Both CO2 in-
sufflation and thoracic wall lifting with the stable camera
trocar of the da Vinci robotic system result in an additional
enlargement of the operation field. The articulated wristed
robotic instruments allow for refinement of the mediastinal
dissection. For obese patients and when otherwise neces-
sary, special long trocars were used. The surgical proce-
dures were generally performed via a left-sided approach;
a right-sided approach was chosen only for specific excep-
tions such as right-sided thymoma.
Patients in the thoracoscopic group had a median age of
37 years (range, 11–74 years). In the robotic group, the me-
dian age was 39 months (range, 7–75 months). The gender
ratio (male:female) was 0.76 for the total population of pa-
tients undergoing robotic thoracoscopic thymectomies and
0.42 for thoracoscopic thymectomies. The percentages of
the degree of severity according to the MGFA classification
were identical for both series (Table 1).Most patients in both
groups had myasthenia gravis class III according to the
MGFA classification. Blood levels of anti-acetylcholine-
receptor antibodies were elevated in 72 and 76 patients for
nonrobotic and robotic thymectomy, respectively.
The main histologic finding in the robotic group was fol-
licular hyperplasia of the thymus (33/74, 45%), whereas
follicular hyperplasia was more dominant (54/79, 68%) in
the nonrobotic thoracoscopic series. For other histologic
findings, a similar distribution was seen in both series as
shown in Figure 1. There were 6 patients with thymoma in
the thoracoscopic group and 11 patients in the robotic group.
The mean operation time for robotic thoracoscopic thy-
mectomies was 187 48minutes (range, 110–310 minutes),
whereas the operation time for thoracoscopic thymectomies
was 198  48 minutes (range, 90–300 minutes).
The conversion rate in the whole robotic series was 1.4%
(1/74). In this case, the surgical procedure was startedery c March 2011
FIGURE 1. Histology of the thymic gland after robotic thymectomy ver-
sus nonrobotic thymectomy. Results are shown in percentage of patients.
rThx, Robotic thymectomy; tThx, nonrobotic thymectomy.
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Sthoracoscopically just to evaluate the possibility of a mini-
mally invasive technique. This patient underwent a conver-
sion to a sternotomy. The histologic findings showed
Masaoka stage III (corresponding to World Health Organi-
zation B3) thymoma. The conversion rate for the thoraco-
scopic series was 1.3% (1/79). With a 30-day zero
mortality, the overall postoperative morbidity rate was
2.7% (2/74) and 2.5% (2/79) for the robotic and thoraco-
scopic procedures, respectively. There was 1 bleeding and
1 phrenic nerve resection due to thymoma involvement in
each group.
The cumulative complete remission rate of myasthenia
gravis for the robotic thoracoscopic thymectomies was
39.25% with a follow-up of 42 months. This was signifi-
cantly improved compared with the thoracoscopic series
(20.3%, P ¼ .01) (Figure 2).DISCUSSION
Blalock and colleagues10 started the first attempts with
a consecutive series of thymectomies for patients with non-FIGURE 2. Cumulative complete remission rates of myasthenia gravis
for robotic and nonrobotic thoracoscopic cohort groups analyzed by the
Kaplan–Meier method.
The Journal of Thoracic and Cathymomatous myasthenia gravis. At the same time, they ini-
tiated the debate about the most appropriate surgical ap-
proach for the thymic gland. Since then, the value of
thymectomy in the treatment of myasthenia gravis has
been supported by many authors.11,12 However, the lack of
controlled studies prevented a higher level of evidence for
thymectomy, resulting in remaining doubts as to the benefit
of thymectomy in the treatment of myasthenia gravis.13
Nevertheless, thymectomy has been gaining acceptance
in the comprehensive therapy of myasthenia gravis. This
has been due to several effects, such as the development
of more minimally invasive radical surgical procedures
and the improvement in the clinical symptoms of myasthe-
nia gravis after thymectomy.14 Because both maximal im-
provement of symptoms and cosmetic results are
important to patients, for most, neither pure extended nor
minimal access surgery alonewill prove satisfactory. There-
fore, radical thymectomy with the lowest degree of inva-
siveness for the patient is crucial. The development and
clinical investigation of more than 14 approaches actually
implemented for thymectomy demonstrates the search for
the optimal combination of these requirements.
Since the start of thoracoscopic procedures in 1994,
a standardized 10-step unilateral 3-trocar thoracoscopic
technique for complete thymectomy has been developed
at the Department of Surgery of Charite-Universit€atsmedi-
zin Berlin.15 This technique was then modified and per-
formed with the da Vinci robotic system beginning in
January 2003.
To evaluate possible advantages of robotic thoracoscopic
thymectomy compared with thoracoscopic thymectomy,
the design of a retrospective cohort study of prospectively
collected data was chosen. This method of evaluation is in
accordance with level 2 of evidence due to the scale of
evidence-based medicine.16
To allow for a cohort analysis, the same number of pa-
tients at the same degree of experience with the respective
operation technique was included. A large number of pa-
tients and a uniform and extended follow-up period for all
patients were further criteria of the study design for this in-
vestigation. Accordingly, the entire thoracoscopic experi-
ence of 79 patients was compared with the first 74 robotic
thymectomies.
The analysis of improvement of myasthenia gravis after
thymectomy was made according to the rules of MGFA.
There was no significant change in the principles of medical
therapy used for symptomatic, immunosuppressive, or res-
cue therapy of myasthenia gravis during the decade of the
cohort analysis. Specifically, no major modifications in
the perioperative management of thymectomy for myasthe-
nia gravis have taken place in our department during this
time. With respect to the percentage of patients receiving
symptomatic immunosuppressive or plasmapheresis ther-
apy, there was no difference between both groups.rdiovascular Surgery c Volume 141, Number 3 675
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mectomy is influenced by many factors. Therefore, factors
such as age, gender, severity of myasthenia gravis, and his-
tology of the thymic gland could be an important aspect of
the cohort analysis.
The overall analyses of the data showed typical myasthe-
nia gravis patient distribution in both groups. This concor-
dant subgroup distribution is an essential prerequisite for
comparison of the cohort group. The operation time in the ro-
botic and thoracoscopic group did not significantly differ. In
a case of large thymoma with involvement of the pericar-
dium, the operation time with the robotic system was 310
minutes because of simultaneous partial pericardium resec-
tion. All procedures were performed in a 3-trocar left-sided
thoracoscopic technique. In case of thymoma, which is pre-
dominant on the right side, we used a right-sided approach.
Although we believe that the thymus can be safely ap-
proached from either side for thoracoscopic or robotic tech-
niques, we have chosen the left access for a number of
reasons, including our experience with an anatomic study.4
The left lobe of the thymus gland is usually larger and ex-
tends down to the pericardiophrenic area. The same observa-
tion was made by other investigators.17 The aortopulmonary
window and the region below the left innominate vein are
frequent sites of ectopic thymic tissue, as pointed out by Jar-
etzki and colleagues.2 In addition, by using the left-sided ap-
proach, we can easily demonstrate the right phrenic nerve to
control complete resection.
Several technical characteristics of the da Vinci robotic
system have proven to be valuable for minimally invasive
surgery18 and for thymectomy in particular.
After thoracoscopic thymectomy, 20.3% of the patients
reached a complete remission of myasthenia gravis. This re-
sult is comparable to previously published large centers’ re-
sults using the same approach.19-22 Therefore, the remission
rate of myasthenia gravis in the nonrobotic cohort group,
which showed a further increase with longer follow-up, is
representative for this surgical technique. In this cohort
study, it was demonstrated that patients had significantly bet-
ter complete remission rates after robotic thoracoscopic
thymectomy (39.25%) compared with patients after thora-
coscopic thymectomy (20.3%). A plausible explanation
for this finding might be improved mediastinal dissection
with robotic technology.Another factor could be the insuffla-
tion with CO2 with subsequent enlargement of the operation
field in the robotic series. In amixed populationwith difficult
anatomic cases, robotic thoracoscopic thymectomymay lead
to more complete thymectomy. Further support may come
from the inclusion of large patient numbers with general ho-
mogeneity due to similar basic parameter distribution and
unified perioperative treatment strategy. The exception of
significantly increased hyperplasia in the thoracoscopic se-
ries could have favored improvement results in this group.
Because this study was not randomized, the results must be676 The Journal of Thoracic and Cardiovascular Surgevaluated critically. The consecutive cohorts may contain
other inhomogeneities in certain subgroups.
The number of patients in each cohort group is far beyond
the learning curve for thoracoscopic thymectomy. An actual
evaluation of the learning curve for robotic lung lobectomy
showed 15 operations to be a sufficient learning curve.23 It
should be taken into consideration that the experience ob-
tained with the thoracoscopic thymectomy may have paved
theway for the robotic thymectomy, and therefore may have
influenced the results of this study to a certain degree.
CONCLUSIONS
The feasibility and efficacy of robotic thoracoscopic thy-
mectomy have been illustrated. An advantage of this ap-
proach over thoracoscopic thymectomy was demonstrated
in this cohort study.
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SDiscussion
Dr Franca Melfi (Pisa, Italy). I have a few points to stress and
some questions for you, Dr Ruckert. The first point. There is
a long-lasting debate concerning the optimal surgical technique
for patients with myasthenia gravis who undergo thymectomy.
The major concern is the necessity to perform a complete thymec-
tomy for immunologic and functional reasons. Because of poten-
tial ectopic thymic tissue in the anterior mediastinal area,
a radical resection is required. So an optimal approach should
combine less invasiveness and maximal radicality. I fully agree
that the robot allows precise anatomic dissection of the thymus;
however, there is still ongoing discussion on whether you should
do it from the left or right or combine them with a cervical or sub-
xiphoid incision. Could you comment on that and why you decided
to use the left side?
Dr Ruckert. My answer should begin with the last part of the
question. This has been described in historical papers in the
1930s of the last century, and again and again, the left main lobe
and additional lobes, thewhole part, even the upper lobe, are larger
than the right part of the thymic gland with exceptions. I showed an
exception. If there is a tumor in the right part, we use the right-
sided approach. We did that several times. I would recommend
that with a tumor or computed tomography scan pronouncing
a right predominant thymic gland, but in most patients, this is
not the case. Radicality is the important thing. The whole stepwise
development of thoracoscopic and then robotic thymectomy was
according to the hypothesis and approval of Jaretzki and col-
leagues’ findings of completeness being the most important thing
for late outcome. This can be proven not only with a complete sta-
ble remission as a main parameter, as I showed, but also with the
postintervention status of the patients according to the MGFA.
I think the results of the series until now are good enough not to
find it necessary to have an extension of the operation in many
cases. These were only a few hybrid procedures together with thor-
acoscopy. But we should be ready to convert at any time, for tech-
nical reasons, for morbidity, for bleeding, for anything, rescue
management is very important, and we should be ready to extend
the operation to a cervical extra incision or something else. But,
again, we did not find it necessary in many cases.The Journal of Thoracic and CaDrMelfi. The second point concerns thymomas. The complete-
ness of a resection is the most statistically significant prognostic
factor. As a standard, surgical management requires thewide open-
ing of the mediastinum and both pleural cavities, which is classi-
cally achieved bymedian sternotomy. In your series, you hadmany
thymomas, some very large size thymomas. At the beginning, were
these unexpected patients or did you select them to undergo the ro-
botic procedure? In regard to the robotic technique, considering
that robotic instruments have a small tip size and a small medias-
tinal space despite CO2 insufflation, how do you manage the thy-
momas, especially the large size of thymoma dissection, safely,
avoiding seeding, which can occur during the manipulation or ma-
neuvers to remove the specimen?
Dr Ruckert. The percentage of patients with thymoma is ap-
proximately 15%. As you can see, this is typical for all the large
series worldwide, 15% to 30% of thymomas in the patients with
myasthenia. The size is not the main criterion, but more than
that, the anatomy, where it is, how it seems to be movable. We
judge according to the computed tomography scan diagnosis.
This is our main finding. Meanwhile, we would not exclude an ex-
cision of the pericardium, as many others do, and there is a discus-
sion in the literature about whether a complete thymectomy has to
be performed with thymoma. I mentioned the early works of Land-
renau, whose first case was a thoracoscopic thymomectomy; Yosh-
ino, in 2001, performed the first robotic thymomectomy, not
a thymectomy; and there is at least one publication that compares
19 and 11 patients with an incomplete thymectomy for thymoma.
Wewould stick to the rule of complete thymectomy; spillage has to
be avoided. I think robotic technology has big advantages, espe-
cially in this respect.
Dr Tomasz Grodzki (Szczecin, Poland). I have one question,
because if I do bilateral thoracoscopy plus cervical incision I
have a strong feeling that I performed a complete procedure, and
how can you explain the big difference in outcome between the ro-
botic and thoracoscopic approaches? Maybe the robotic approach
is easier, a little bit faster, but I can’t understand why the outcome
is so different.
Dr Ruckert. I agree with that question. This was our question,
too. I cannot ignore the big influence of the real learning curve on
the whole procedure and the outcome; perhaps this was only with
the thoracoscopic approach. We heard in all the robotic sessions
that it might not be necessary to be a minimally invasive surgeon
before learning a robotic approach. This is an interesting discus-
sion. I would say it helped a lot. The second point is we never
used CO2 during the thoracoscopic experience, and we know
how beautiful the operation field can be extended. If we compare
as a last step during the robotic procedure from time to time with
a 5-mm trocar from the right side, we check for radicality, we find
a beautiful, very alone, right phrenic nerve. So there is no necessity
for a second side thoracoscopic approach.rdiovascular Surgery c Volume 141, Number 3 677
